WO2001025421B1 - Materials and method for detecting interaction of cftr polypeptides - Google Patents

Materials and method for detecting interaction of cftr polypeptides

Info

Publication number
WO2001025421B1
WO2001025421B1 PCT/US2000/027900 US0027900W WO0125421B1 WO 2001025421 B1 WO2001025421 B1 WO 2001025421B1 US 0027900 W US0027900 W US 0027900W WO 0125421 B1 WO0125421 B1 WO 0125421B1
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cftr
subject invention
materials
proteins
Prior art date
Application number
PCT/US2000/027900
Other languages
French (fr)
Other versions
WO2001025421A3 (en
WO2001025421A2 (en
Inventor
John L Teem
Original Assignee
Univ Florida State Res Found
John L Teem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida State Res Found, John L Teem filed Critical Univ Florida State Res Found
Priority to AU11939/01A priority Critical patent/AU1193901A/en
Priority to US10/089,875 priority patent/US7238474B1/en
Publication of WO2001025421A2 publication Critical patent/WO2001025421A2/en
Publication of WO2001025421A3 publication Critical patent/WO2001025421A3/en
Publication of WO2001025421B1 publication Critical patent/WO2001025421B1/en
Priority to US11/821,812 priority patent/US8288107B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/20—Detection means characterised by being a gene reporter based analysis
    • C12Q2565/201—Two hybrid system

Abstract

The subject invention concerns materials and methods for detecting the interaction of CFTR proteins. In one embodiment, the method can be used to determine whether one CFTR polypeptide interacts with a second CFTR polypeptide. The subject invention also concerns materials and methods for screening for drugs or compositions that can restore or enhance interaction of CFTR proteins containing mutation(s) that reduce or prevent dimerization of the proteins. The assay of the present invention can be used to screen a large number of compounds in a high throughput format. The subject invention also pertains to host cells useful in the methods of the invention. The subject invention also concerns compositions and methods for treating patients afflicted with cystic fibrosis.
PCT/US2000/027900 1999-10-06 2000-10-06 Materials and method for detecting interaction of cftr polypeptides WO2001025421A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU11939/01A AU1193901A (en) 1999-10-06 2000-10-06 Materials and method for detecting interaction of cftr polypeptides
US10/089,875 US7238474B1 (en) 1999-10-06 2000-10-06 Materials and methods for detecting interaction of CFTR polypeptides
US11/821,812 US8288107B2 (en) 1999-10-06 2007-06-25 Materials and methods for detecting interaction of CFTR polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15799699P 1999-10-06 1999-10-06
US60/157,996 1999-10-06
US18189200P 2000-02-11 2000-02-11
US60/181,892 2000-02-11
US18237300P 2000-02-14 2000-02-14
US60/182,373 2000-02-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/089,875 A-371-Of-International US7238474B1 (en) 1999-10-06 2000-10-06 Materials and methods for detecting interaction of CFTR polypeptides
US11/821,812 Continuation US8288107B2 (en) 1999-10-06 2007-06-25 Materials and methods for detecting interaction of CFTR polypeptides

Publications (3)

Publication Number Publication Date
WO2001025421A2 WO2001025421A2 (en) 2001-04-12
WO2001025421A3 WO2001025421A3 (en) 2001-08-30
WO2001025421B1 true WO2001025421B1 (en) 2001-09-27

Family

ID=27388112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027900 WO2001025421A2 (en) 1999-10-06 2000-10-06 Materials and method for detecting interaction of cftr polypeptides

Country Status (3)

Country Link
US (2) US7238474B1 (en)
AU (1) AU1193901A (en)
WO (1) WO2001025421A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144860A1 (en) * 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Correctors acting through msd1 of cftr protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543399A (en) 1989-08-22 1996-08-06 Hsc Research & Development Limited Partnership Cystic fibrosis transmembrane conductance regulator (CFTR) protein
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5674898A (en) 1990-03-05 1997-10-07 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5939536A (en) 1990-03-05 1999-08-17 Genzyme Corporation Methods for purifying cystic fibrosis transmembrane conductance regulation
US5981714A (en) 1990-03-05 1999-11-09 Genzyme Corporation Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
CA2037478A1 (en) 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
US7118911B1 (en) 1990-03-05 2006-10-10 Genzyme Corporation DNA molecules stabilized for propagation in bacterial cells that encode cystic fibrosis transmembrane conductance regulator
AU6903594A (en) 1993-04-23 1994-11-21 University Of Iowa Research Foundation, The Method of assaying for drugs which restore function of mutant cftr protein
US5900360A (en) 1996-04-10 1999-05-04 Welch; William J. Correction of genetic defects using chemical chaperones
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6316223B1 (en) * 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system

Also Published As

Publication number Publication date
WO2001025421A3 (en) 2001-08-30
US20080167259A1 (en) 2008-07-10
WO2001025421A2 (en) 2001-04-12
US8288107B2 (en) 2012-10-16
AU1193901A (en) 2001-05-10
US7238474B1 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
CA2413156A1 (en) Expression vectors
NZ504114A (en) Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability
CA2262920A1 (en) Method for identifying compounds affecting rna/rna binding protein interactions
CA2173975A1 (en) Recombinant adenoviral vector and methods of use
WO2002009836A3 (en) Methods for solid phase nanoextraction and desorption
CA2171982A1 (en) Drug Binding Protein
WO2002083872A3 (en) Methods and products of cleaving ssdna using oligonucleotides to form restriction sites
EP1004674A4 (en) Human adamts-1 protein, gene coding for the same, pharmaceutical composition, and method for immunologically assaying human adamts-1 protein
AU2744200A (en) Determining protein function and interaction from genome analysis
WO2004024750A3 (en) Cd44-binding ligands
WO2001079481A8 (en) Methods of constructing display libraries of genetic packages for members of a diverse family of peptides
CA2302147A1 (en) Methods for protein screening
NO962084L (en) DNA sequence encoding a BMP receptor
AU1911200A (en) Methods and compositions to lower plasma cholesterol levels
WO2001025421A3 (en) Materials and method for detecting interaction of cftr polypeptides
AU5789499A (en) (neisseria meningitidis) polypeptide, nucleic acid sequence and uses thereof
WO2000075324A3 (en) Recombinant prion-like genes and proteins and materials and methods comprising same
EP1169641A4 (en) Proteome mining
AU8636098A (en) Ion-sensitive sensor devices and analytical methods using them
NO941810L (en) Dry Process for Particles, Dry-Prepared Particles Obtained in This Way, and Pharmaceutical Compositions Containing Such Particles
Jarrold et al. An effective skeletal muscle prefractionation method to remove abundant structural proteins for optimized two‐dimensional gel electrophoresis
GB9710762D0 (en) Binding complexes
AU7828698A (en) Detection of loss of the wild-type (hu)bub1 gene
DE69623480D1 (en) IMPROVEMENTS RELATING TO SCREENING PROCEDURES
AU5692699A (en) Apparatus for rapid protein and polypeptide sequence analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP